Skip to main content

Building a leading microbiome company in oncology

We are a clinical-stage microbiome therapeutics company aiming to
improve survival in cancer.

See News

Corporate profile

We are a clinical-stage microbiome therapeutics company aiming to restore and modulate patient-microbiome symbiosis to improve survival in cancer. To do so, we are developing a novel class of microbiome drug candidates: Microbiome Ecosystem Therapies (MET). MET are high-diversity, high-richness, indication-specific products aiming to leverage the full functional diversity of a microbiome ecosystem. Our MET drug development platform leverages gutPrint®, our proprietary AI-based computational biology and our proprietary cGMP manufacturing capacities to deliver innovative new drugs for the treatment of graft-vs-host-disease , the prevention of complications of HSCT for patients with liquid tumors and the improvement of response to immune checkpoint inhibitors in solid tumors. Our team combines expertise ranging from microbiology to data science to oncology and benefits from the commitment of world-leading scientists.

Press Releases

Press Releases

Details of all stabilization transactions

Not for release, publication or distribution, in whole or in part, directly or indirectly in…
Press Releases
Opérations de stabilisation
Press Releases
MaaT Pharma to Provide Additional Results from Phase II Trial and Expanded Access Program on MaaT013 in Oral Presentation at 63rd American Society of Hematology (ASH) Annual Meeting
Press Releases
MaaT Pharma announces successful Initial Public Offering on the regulated market of Euronext Paris
Press Releases
MaaT Pharma launches its initial public offering on the regulated market of Euronext in Paris

See more

Videos

Media

Media

MaaT Pharma veut lever 35 millions d’euros en Bourse

Media
MaaT Pharma s’introduit sur Euronext
Media
MaaT Pharma espère lever au moins 35 M€ en Bourse

See more